News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immunomedics, Inc. (IMMU) Develops Novel Agents Targeting Renal Cell Carcinoma


4/4/2012 9:39:46 AM

CHICAGO, April 3, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today presented results from two preclinical studies on the development of Dock-and-Lock (DNL) derived novel therapeutic agents targeting solid tumors, including renal cell carcinomas (RCC).

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES